CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 152 enrolled
Drug / intervention
Colchicine +1 moredrug
Likely dose
Colchicine 0.6 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05017571
NCT05017571Phase 2Completed

COLSIO Trial: Phase II Randomized, Controlled Trial of Colchicine to Suppress Inflammation and Improve Insulin Resistance in Adults and Adolescents With Obesity

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)·interventional·Posted Aug 24, 2021·Updated Sep 5, 2025

In Brief

A Phase 2 clinical trial evaluating Colchicine and Placebo for Obesity and 2 related conditions. Completed, enrolled 152 participants across 1 site.

Detailed Summary

Background: About 40 percent of adults and 20 percent of adolescents in the U.S. have a body mass index over 30 kg/m2. Being overweight may lead to a state of low-level inflammation. This may cause health problems. Researchers want to see if an anti-inflammatory medicine can help. Objective: To learn if colchicine can improve metabolism in people who have high body weight, increased inflammation, and high insulin in the blood but who have not yet developed high blood sugar. Eligibility: People aged 12 and older with high body weight who may have increased inflammation and high insulin in the blood. Healthy adult volunteers are also needed. Design: Participants will be screened with the following: Medical history Physical exam Fasting blood tests Urine tests Electrocardiogram Dual energy x-ray absorptiometry (They will lie on a table while a camera passes over their body.) Stool sample and 24-hour food diary (optional) Participants will have 3 study visits and 3 phone check-ins. At visits, they will repeat some screening tests. Healthy volunteers will have the baseline visit only. They will not get the study drug. At the baseline visit, participants will have an Oral Glucose Tolerance Test (OGTT). For this, they will drink a sweet liquid and then give blood samples. They will get a 12-week supply of the study drug or placebo to take daily by mouth. Participants will have study visits 6 weeks and 12 weeks after they started taking the study drug. At the 12-week visit, they will repeat the OGTT. Participation will last for 3 (Omega) to 4 months. ...

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20222023202420252026
First PostedAug 24, 2021
Enrollment StartNov 8, 2021
Primary CompletionSep 2, 2025
TodayJul 1, 2026
Enrollment to primary: 3.8 yearsPosted 4.9 years ago

Interventions

Colchicinedrug

Colchicine 1 capsule (0.6 mg) per day

Placebodrug

Placebo 1 capsule per day